Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: A Pandora Box to Explain Prognostic Differences

Hyun Kuk Kim; Udaya S. Tantry; Hyun-Woong Park; Tobias Geisler; Diana Gorog; Paul A Gurbel; Young-Hoon Jeong

doi:10.4070/kcj.2020.0537

Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: A Pandora Box to Explain Prognostic Differences

Hyun Kuk Kim, Udaya S. Tantry, Hyun-Woong Park, Tobias Geisler, Diana Gorog, Paul A Gurbel, Young-Hoon Jeong

Research output: Contribution to journal › Article › peer-review

14 Downloads (Pure)

Abstract

Arterial and venous atherothrombotic events are finely regulated processes involving a complex interplay between vulnerable blood, vulnerable vessel, and blood stasis. Vulnerable blood ('thrombogenicity') comprises complex interactions between cellular components and plasma factors (inflammatory, procoagulant, anticoagulant, and fibrinolytic factors). The extent of thrombogenicity may determine the progression of atheroma and the clinical manifestation of atherothrombotic events, with the highest thrombogenicity in African Americans and lowest in East Asians. Inherent thrombogenicity may influence clinical efficacy and safety of specific antithrombotic treatments in high-risk patients, which may in part explain the observation that East Asian patients have reduced anti-ischemic benefits and elevated bleeding risk with antithrombotic therapy compared to Caucasian patients. In this review, we discuss available evidence regarding the racial differences in thrombogenicity and its impact on clinical outcomes among patients with atherosclerotic cardiovascular disease.

Original language	English
Pages (from-to)	202-221
Number of pages	20
Journal	Korean Circulation Journal (KCJ)
Volume	51
Issue number	3
Early online date	9 Feb 2021
DOIs	https://doi.org/10.4070/kcj.2020.0537
Publication status	Published - 1 Mar 2021

Keywords

Antithrombotic treatment
Coagulation
Inflammation
Race
Thrombogenicity

Access to Document

10.4070/kcj.2020.0537Licence: CC BY-NC

Ethnic Diff
© 2021. The Korean Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Final published version, 3.49 MBLicence: CC BY-NC

Cite this

@article{51a982851410411782cff55768894124,

title = "Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: A Pandora Box to Explain Prognostic Differences",

abstract = "Arterial and venous atherothrombotic events are finely regulated processes involving a complex interplay between vulnerable blood, vulnerable vessel, and blood stasis. Vulnerable blood ('thrombogenicity') comprises complex interactions between cellular components and plasma factors (inflammatory, procoagulant, anticoagulant, and fibrinolytic factors). The extent of thrombogenicity may determine the progression of atheroma and the clinical manifestation of atherothrombotic events, with the highest thrombogenicity in African Americans and lowest in East Asians. Inherent thrombogenicity may influence clinical efficacy and safety of specific antithrombotic treatments in high-risk patients, which may in part explain the observation that East Asian patients have reduced anti-ischemic benefits and elevated bleeding risk with antithrombotic therapy compared to Caucasian patients. In this review, we discuss available evidence regarding the racial differences in thrombogenicity and its impact on clinical outcomes among patients with atherosclerotic cardiovascular disease.",

keywords = "Antithrombotic treatment, Coagulation, Inflammation, Race, Thrombogenicity",

author = "Kim, {Hyun Kuk} and Tantry, {Udaya S.} and Hyun-Woong Park and Tobias Geisler and Diana Gorog and Gurbel, {Paul A} and Young-Hoon Jeong",

note = " {\textcopyright} 2021. The Korean Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ",

year = "2021",

month = mar,

day = "1",

doi = "10.4070/kcj.2020.0537",

language = "English",

volume = "51",

pages = "202--221",

journal = "Korean Circulation Journal (KCJ)",

issn = "1738-5520",

publisher = "Korean Society of Circulation",

number = "3",

}

TY - JOUR

T1 - Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: A Pandora Box to Explain Prognostic Differences

AU - Kim, Hyun Kuk

AU - Tantry, Udaya S.

AU - Park, Hyun-Woong

AU - Geisler, Tobias

AU - Gorog, Diana

AU - Gurbel, Paul A

AU - Jeong, Young-Hoon

N1 - © 2021. The Korean Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PY - 2021/3/1

Y1 - 2021/3/1

N2 - Arterial and venous atherothrombotic events are finely regulated processes involving a complex interplay between vulnerable blood, vulnerable vessel, and blood stasis. Vulnerable blood ('thrombogenicity') comprises complex interactions between cellular components and plasma factors (inflammatory, procoagulant, anticoagulant, and fibrinolytic factors). The extent of thrombogenicity may determine the progression of atheroma and the clinical manifestation of atherothrombotic events, with the highest thrombogenicity in African Americans and lowest in East Asians. Inherent thrombogenicity may influence clinical efficacy and safety of specific antithrombotic treatments in high-risk patients, which may in part explain the observation that East Asian patients have reduced anti-ischemic benefits and elevated bleeding risk with antithrombotic therapy compared to Caucasian patients. In this review, we discuss available evidence regarding the racial differences in thrombogenicity and its impact on clinical outcomes among patients with atherosclerotic cardiovascular disease.

AB - Arterial and venous atherothrombotic events are finely regulated processes involving a complex interplay between vulnerable blood, vulnerable vessel, and blood stasis. Vulnerable blood ('thrombogenicity') comprises complex interactions between cellular components and plasma factors (inflammatory, procoagulant, anticoagulant, and fibrinolytic factors). The extent of thrombogenicity may determine the progression of atheroma and the clinical manifestation of atherothrombotic events, with the highest thrombogenicity in African Americans and lowest in East Asians. Inherent thrombogenicity may influence clinical efficacy and safety of specific antithrombotic treatments in high-risk patients, which may in part explain the observation that East Asian patients have reduced anti-ischemic benefits and elevated bleeding risk with antithrombotic therapy compared to Caucasian patients. In this review, we discuss available evidence regarding the racial differences in thrombogenicity and its impact on clinical outcomes among patients with atherosclerotic cardiovascular disease.

KW - Antithrombotic treatment

KW - Coagulation

KW - Inflammation

KW - Race

KW - Thrombogenicity

UR - http://www.scopus.com/inward/record.url?scp=85102642788&partnerID=8YFLogxK

U2 - 10.4070/kcj.2020.0537

DO - 10.4070/kcj.2020.0537

M3 - Article

C2 - 33655720

SN - 1738-5520

VL - 51

SP - 202

EP - 221

JO - Korean Circulation Journal (KCJ)

JF - Korean Circulation Journal (KCJ)

IS - 3

ER -

Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: A Pandora Box to Explain Prognostic Differences

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this